We are live on ! Find out more
TAK icon

Takeda Pharmaceutical
TAK

283 hedge funds and large institutions have $1.15B invested in Takeda Pharmaceutical in 2024 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 90 increasing their positions, 102 reducing their positions, and 55 closing their positions.

New
Increased
Maintained
Reduced
Closed

671% more call options, than puts

Call options by funds: $23.6M | Put options by funds: $3.06M

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

5% more capital invested

Capital invested by funds: $1.09B → $1.15B (+$58.3M)

0.39% less ownership

Funds ownership: 4.94% → 4.56% (-0.39%)

10% less funds holding

Funds holding: 313 → 283 (-30)

12% less repeat investments, than reductions

Existing positions increased: 90 | Existing positions reduced: 102

47% less first-time investments, than exits

New positions opened: 29 | Existing positions closed: 55

Holders
283
Holders Change
-30
Holders Change %
-9.58%
% of All Funds
4.09%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
29
Increased
90
Reduced
102
Closed
55
Calls
$23.6M
Puts
$3.06M
Net Calls
+$20.5M
Net Calls Change
-$3.89M

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$26.8M
2
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
+$12.6M
3
CAC
Cowen and Company
New York
+$7.02M
4
VanEck Associates
VanEck Associates
New York
+$4.71M
5
Citadel Advisors
Citadel Advisors
Florida
+$4.01M

Top Sellers

Rank Fund Capital Flow
1
MIP
Mondrian Investment Partners
United Kingdom
-$57.5M
2
Macquarie Group
Macquarie Group
Australia
-$15.9M
3
Bank of America
Bank of America
North Carolina
-$8.17M
4
BlackRock
BlackRock
New York
-$7.39M
5
Goldman Sachs
Goldman Sachs
New York
-$6.51M
Name Holding Trade Value Shares
Change 		Change in
Stake
Pathstone Holdings
26
Pathstone Holdings
New Jersey
$5.52M -$76.6K -5,787 -1%
Royal Bank of Canada
27
Royal Bank of Canada
Ontario, Canada
$5.44M +$285K +21,561 +5%
Federated Hermes
28
Federated Hermes
Pennsylvania
$4.93M -$2.78M -209,700 -36%
QCM
29
Quantinno Capital Management
New York
$4.55M +$1.38M +104,386 +42%
Hudson Bay Capital Management
30
Hudson Bay Capital Management
Connecticut
$4.53M +$2.32M +175,000 +100%
XC
31
XY Capital
Hong Kong
$4.45M +$1.61M +121,771 +55%
SEI Investments
32
SEI Investments
Pennsylvania
$4.32M -$519K -39,235 -11%
MNA
33
Manning & Napier Advisors
New York
$4.1M +$4.19M +316,690 New
Citadel Advisors
34
Citadel Advisors
Florida
$4.04M +$4.01M +302,886 +3,294%
Janus Henderson Group
35
Janus Henderson Group
United Kingdom
$4M +$1.48M +111,894 +57%
BFG
36
Bleakley Financial Group
New Jersey
$3.88M +$152K +11,449 +4%
SW
37
Simplicity Wealth
New Jersey
$3.88M +$152K +11,449 +4%
QCM
38
QRG Capital Management
Illinois
$3.5M -$618K -46,649 -15%
American Century Companies
39
American Century Companies
Missouri
$3.4M +$230K +17,363 +7%
RJA
40
Raymond James & Associates
Florida
$3.31M +$170K +12,862 +5%
OAM
41
Oppenheimer Asset Management
New York
$3.28M +$304K +22,979 +10%
SGI
42
Summit Global Investments
Utah
$2.89M -$455K -34,378 -13%
OMC
43
Old Mission Capital
Illinois
$2.89M +$1.64M +124,087 +125%
HFS
44
Hantz Financial Services
Michigan
$2.84M -$143K -10,837 -5%
Stifel Financial
45
Stifel Financial
Missouri
$2.8M -$1.03M -78,143 -27%
LPL Financial
46
LPL Financial
California
$2.22M -$1.47K -111 -0.1%
Mercer Global Advisors
47
Mercer Global Advisors
Colorado
$2.2M -$527K -39,782 -19%
CCA
48
Catalyst Capital Advisors
New York
$2.15M -$39.7K -3,000 -2%
LWAM
49
Legacy Wealth Asset Management
Minnesota
$2.13M +$90.9K +6,868 +4%
Charles Schwab
50
Charles Schwab
California
$2.06M +$606K +45,770 +40%
1
2
3 4 5

TAK Hedge Fund Activity: Q2 2024 in Review

283 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q2 2024, worth a combined $1.15B — up 5.4% from $1.09B a quarter earlier.

Sellers outnumbered buyers: 55 funds closed out of TAK and 29 opened new positions — a net loss of 26 holders — while 102 trimmed existing stakes and 90 added.

The largest buyer was Millennium Management, adding an estimated $26.8M. The largest seller was Mondrian Investment Partners, cutting an estimated $57.5M.

  • 283 institutional investors held Takeda Pharmaceutical (TAK) as of Q2 2024, down from 313 in Q1 2024.
  • Funds reported $1.15B of Takeda Pharmaceutical stock for Q2 2024, up 5.4% quarter-over-quarter.
  • 29 funds opened new Takeda Pharmaceutical positions in Q2 2024 and 55 closed out, a net change of -26 holders.
  • The largest Takeda Pharmaceutical buyer in Q2 2024 was Millennium Management, an estimated $26.8M added.
  • The largest Takeda Pharmaceutical seller in Q2 2024 was Mondrian Investment Partners, an estimated $57.5M sold.

Based on aggregated 13F filings for Q2 2024.